Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Sachdeva, Naresh ^a   Sehgal, Shobha ^a   Arora, Sunil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; POL PROTEIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CODON; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; INFANT; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; STRUCTURAL GENE; CONTROLLED STUDY; FREQUENCY ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; INDIA; INFANT; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ZIDOVUDINE;

EID: 25144472629     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: 10.1186/1758-2652-7-3-68     Document Type: Article

References (34)

1. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
2. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999;354:729-733.
3. Little SJ, Holte S, Routy JP, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
4. Juethner SN, Williamson C, Ristig MB, et al. Non nucleoside reverse transcriptase inhibitor resistance among antiretroviral-naïve HIV-positive pregnant women. J Acquir Immune Defic Syndr. 2003;32:153-156.
5. Domingo E, Holland JJ. Mutation rates and rapid evolution of RNA viruses. In: Morse SS, ed. Evolutionary Biology of Viruses. New York: Raven Press; 1994:161-184.
6. Najera I, Holguia A, Quinones-Mateu ME, et al. Pol gene quasi species of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995;69:23-31.
7. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984-1991.
8. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI group. AIDS. 1999;13:1705-1709.
9. Brenner B, Routy JP, Quan Y, et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to super infection. AIDS. 2004;18:1653-1660.
10. Palmiter RD, Chen HY, Messing A, Brinster RL. SV 40 enhancer and large T antigen are instrumental in development of choroids plexus tumors in transgenic mice. Nature. 1985;316:457-460.
11. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991; 5:137-144.
12. Soto-Ramirez LE, Tripathy S, Renjifo B, Essex M. HIV-1 pol sequences from India fit distinct subtype pattern. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:299-307.
13. Wainberg MA, Salomon H, Gu H, et al. Development of HIV-1 resistance to (-) 2;-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995;9:351-357.
14. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of Zidovidine resistance mutations during treatment of 18 Human Immunodeficiency Virus-positive subjects. J Infect Dis. 1992;165:105-110.
15. de Jong MD, Veenstra J, Stilianakis NI, et al. Host parasite dynamics and outgrowth of virus containing a single K 70 R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by Zidovudine. Proc Natl Acad Sci U S A. 1996;93:5501-5506.
16. Van Houtte M, Lecocq P, Bachelor L. Prevalence and quantitative phenotypic resistance patterns of specific nucleoside analogue mutation combinations and of mutations 44 and 118 in reverse transcriptase in a large dataset of recent HIV-1 clinical isolates. Antivir Ther. 2003;8:S42.
17. Merchant RH, Damania K, Gilada IS, et al. Strategy for preventing vertical transmission of HIV: Bombay experience. Indian Pediatr. 2001;38:132-8.
18. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsua H. Comparative fitness of multi dideoxynucleoside resistant Human Immunodeficiency Virus type-1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol. 1999;73:5356-5363.
19. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1 seroconverters in the USA, 1993-1998. J Infect Dis. 2000;182:330-333.
20. Ammaranond P, Cunningham P, Oelrichs R, et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol. 2003;26:153-161.
21. Kamkamidze G, Sullivan T, Charabonneau T. Occurrence of HIV-1 reverse transcriptase gene mutation at codon-215 in HIV infected infants. J Clin Virol. 2001;22:143-148.
22. Grossman Z, Vardinon N, Schapiro M, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
23. Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, Segondy M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr. 2004;35:329-336.
24. Cesaire R, Dos Santos G, Sylvie A, Odile B, Guy S, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naïve patients in Martinique, French West Indies. J Acquir Immune Defic Syndr. 1999;22:401-405.
25. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug-naïve Ugandan adults. AIDS Res Hum Retroviruses. 2000;16:807-813.
26. Delgado E, Leon-Ponte M, Villahermosa ML, et al. Analysis of HIV-1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UN-AIDS study. AIDS Res Hum Retroviruses. 2001;17:753-758.
27. Brinderio RM, Diaz RS, Sabino EC, et al. Brazilian network for HIV drug resistance surveillance (HIV-B Res Nt): a study of chronically infected individuals. AIDS. 2003;17:1063-1069.
28. Toni TD, Recordon-Pinson P, Fleury HJ, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivory: ANRS 1257 study. AIDS Res Hum Retroviruses. 2003;19:713-717.
29. Horban A, Stanczak JJ, Bakowska E, et al. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naïve individuals from the Warsaw Cohort. Infection. 2002;30:356-359.
30. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-188.
31. Paolucci S, Baldanti F, Campanini G, et al. Analysis of HIV drug-resistant quasi-species in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naïve and HAART patients. J Med Virol. 2001;65:207-217.
32. Servais J, Lambert C, Fontaine E, et al. Comparison of DNA sequencing and a Line Probe Assay for detection of Human Immunodeficiency Virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol. 2001;39:454-459.
33. Van Laethem K, Van Vaerenbergh K, Schmit J-C, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr. 1999;22:107.
34. Adje C, Cheingsoug R, Roebs TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug resistance strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2001;25:501-506.